European Pharmaceutical Review
FEBRUARY 27, 2024
Previous roles The MHRA highlighted Dame June Raine has been Chief Executive Officer of the MHRA since August 2019. Her educational background includes training in medicine in Oxford after completing a master’s degree by research in Pharmacology.
European Pharmaceutical Review
AUGUST 23, 2022
The researchers studied 254 VA patients who were diagnosed with PTSD and hepatitis C between October 1999 and September 2019. Many people have PTSD, but there [are] few effective pharmacologic treatments and limited drug development for PTSD,” commented Gradus. The findings are to be published in the American Journal of Epidemiology.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JANUARY 12, 2023
The Attorney General of Alabama has threatened to use an obscure law passed in 2006 to prosecute women who terminate a pregnancy using pharmacological means, shortly after the FDA made access to the drugs easier.
European Pharmaceutical Review
MAY 2, 2023
In 2019, the pharmaceutical industry spent $83 billion on R&D, which is about 10 times what the industry spent per year in the 1980s, 4 yet the average duration to develop a new medicine is still around 10-15 years. About the authors Dr Nils Eckardt joined BeiGene in February 2019 as Vice President, Medical Affairs, Europe.
MedCity News
JUNE 16, 2023
Similarly, a 2019 study found rural residents had a five-year relative cancer survival that was 5.2% Trial access equity and inclusivity are important considerations for sponsors given the results of a 2021 analysis of U.S. lower than metropolitan or urban residents and a 10% increase in risk of death after adjustment for multiple factors.
European Pharmaceutical Review
MARCH 11, 2024
About the author Sherene Min, MD, MPH, is Vice President of Global Clinical Development at ViiV Healthcare , a role she assumed in October 2019. With therapeutic expertise in HIV, hepatology and rare diseases, Sherene has additional expertise in clinical pharmacology and drug safety.
Legacy MEDSearch
AUGUST 25, 2022
Despite improvements in patient care pathways, widespread use of reperfusion strategies, and adjuvant pharmacological therapies, the one-year mortality rate after STEMI in high-risk patients has plateaued over the past decade at 14% [1]. The PiCSO Impulse System received ‘Breakthrough Designation’ from the FDA in 2019 and the CE-Mark in 2020.
Expert insights. Personalized for you.
97 
Let's personalize your content